LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) (IMUC), a biotechnology company, announced today that it has signed a research agreement with Antitope Ltd. for the humanization of IMUC’s monoclonal antibodies. IMUC is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential.
